Related references
Note: Only part of the references are listed.Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) and Neurodegenerative Disorders
Yu-Chang Chen et al.
MOLECULAR NEUROBIOLOGY (2012)
Palmitoylethanolamide Protects Against the Amyloid-β25-35-Induced Learning and Memory Impairment in Mice, an Experimental Model of Alzheimer Disease
Giuseppe D'Agostino et al.
NEUROPSYCHOPHARMACOLOGY (2012)
Neuroprotective Activities of Palmitoylethanolamide in an Animal Model of Parkinson's Disease
Emanuela Esposito et al.
PLOS ONE (2012)
PPARs at the crossroads of lipid signaling and inflammation
Walter Wahli et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2012)
New Insights into the Role of Peroxisome Proliferator-Activated Receptors in Regulating the Inflammatory Response after Tissue Injury
Miriam D. Neher et al.
PPAR RESEARCH (2012)
The Role of PPARβ/δ in the Management of Metabolic Syndrome and its Associated Cardiovascular Complications
Elisa Benetti et al.
Endocrine Metabolic & Immune Disorders-Drug Targets (2012)
Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury
Emanuela Esposito et al.
BRAIN BEHAVIOR AND IMMUNITY (2011)
The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases
Sandeep Tyagi et al.
JOURNAL OF ADVANCED PHARMACEUTICAL TECHNOLOGY & RESEARCH (2011)
Palmitoylethanolamide modulates pentobarbital-evoked hypnotic effect in mice Involvement of allopregnanolone biosynthesis
Oscar Sasso et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2010)
Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain
Harald S. Hansen
EXPERIMENTAL NEUROLOGY (2010)
Cannabinoid activation of peroxisome proliferator-activated receptors: Potential for modulation of inflammatory disease
S. E. O'Sullivan et al.
IMMUNOBIOLOGY (2010)
Evidence for the Role of Peroxisome Proliferator-Activated Receptor-β/δ in the Development of Spinal Cord Injury
Irene Paterniti et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Peroxisome Proliferator-Activated Receptor (PPAR)β /δ: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome
Teresa Coll et al.
Current Molecular Pharmacology (2010)
Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-κB nuclear signalling in dorsal root ganglia
Giuseppe D'Agostino et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Behavioral Effects of CB2 Cannabinoid Receptor Activation and Its Influence on Food and Alcohol Consumption
E. S. Onaivi et al.
DRUG ADDICTION: RESEARCH FRONTIERS AND TREATMENT ADVANCES (2008)
Peroxisome Proliferator-activated Receptor γ Down-regulates Follistatin in Intestinal Epithelial Cells through SP1
Brian M. Necela et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury
Tiziana Genovese et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Integration of metabolism and inflammation by lipid-activated nuclear receptors
Steven J. Bensinger et al.
NATURE (2008)
The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARγ receptors and neurotrophic factors
Barbara Costa et al.
PAIN (2008)
Thiazolidinedione class of peroxisome proliferator-activated receptor γ agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats
Seung-Won Park et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Altered PPARγ expression and activation after transient focal ischemia in rats
N. A. Victor et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2006)
Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion:: Effects of the PPAR-α agonist WY14643
Massimo Collino et al.
FREE RADICAL BIOLOGY AND MEDICINE (2006)
Neuronal expression of peroxisome proliferator-activated receptor-gamma (PPARγ) and 15d-prostaglandin J2 -: Mediated protection of brain after experimental cerebral ischemia in rat
Zhishuo Ou et al.
BRAIN RESEARCH (2006)
Basso mouse scale for locomotion detects differences in recovery after spinal cord in ury in five common mouse strains
DM Basso et al.
JOURNAL OF NEUROTRAUMA (2006)
Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli
K Maresz et al.
JOURNAL OF NEUROCHEMISTRY (2005)
The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice
B Schütz et al.
JOURNAL OF NEUROSCIENCE (2005)
Role of endogenous ligands for the peroxisome proliferators activated receptors alpha in the secondary damage in experimental spinal cord trauma
T Genovese et al.
EXPERIMENTAL NEUROLOGY (2005)
Corepressors selectively control the transcriptional activity of PPARγ in adipocytes
HP Guan et al.
GENES & DEVELOPMENT (2005)
Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis
M Kiaei et al.
EXPERIMENTAL NEUROLOGY (2005)
PPARs in diseases: Control mechanisms of inflammation
R Kostadinova et al.
CURRENT MEDICINAL CHEMISTRY (2005)
The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide
J Lo Verme et al.
MOLECULAR PHARMACOLOGY (2005)
Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-α) in the development of inflammatory bowel disease in mice
S Cuzzocrea et al.
LABORATORY INVESTIGATION (2004)
Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS
S Moreno et al.
NEUROSCIENCE (2004)
Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation
T Dehmer et al.
JOURNAL OF NEUROCHEMISTRY (2004)
A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia
WP Farquhar-Smith et al.
ANESTHESIOLOGY (2003)
Up-regulation of fatty acid metabolizing-enzymes mRNA in rat spinal cord during persistent peripheral local inflammation
A Benani et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2003)
Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease
T Breidert et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Peroxisome proliferator-activated receptor-γ agonists prevent experimental autoimmune encephalomyelitis
DL Feinstein et al.
ANNALS OF NEUROLOGY (2002)
Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB1 and CB2-like receptors
WP Farquhar-Smith et al.
PAIN (2002)
Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat
S Conti et al.
BRITISH JOURNAL OF PHARMACOLOGY (2002)
Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis
A Diab et al.
JOURNAL OF IMMUNOLOGY (2002)
Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors
L De Petrocellis et al.
FEBS LETTERS (2001)
Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide
A Calignano et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2001)
Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide
RA Ross et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ)
JM Peters et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Share Paper
